Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reiterated at Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a report released on Wednesday,Benzinga reports. They currently have a $300.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s target price would suggest a potential upside of 26.49% from the stock’s previous close. A […]